Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction
Patrick Terheyden
*
, Angela Krackhardt, Thomas Eigentler
*
Corresponding author for this work
Clinic of Dermatology, Allergology and Venerology
Technical University of Munich
University of Tubingen
6
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Systemic Therapy
100%
Melanoma
100%
Immune Checkpoint Inhibitor
100%
Overall Survival
75%
Hazard Ratio
75%
MEK Inhibitor
50%
Recurrent Disease
25%
Immunity
25%
Brain Metastasis
25%
T Cell
25%
Metastatic Melanoma
25%
Death Receptor
25%
Dacarbazine
25%
Pembrolizumab
25%
Nivolumab
25%
Cytotoxic T-Cell
25%
Metastasectomy
25%
Immunocompetent Cell
25%
Monotherapy
25%
Melanoma Cell
25%
CTLA-4
25%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Systemic Treatment
100%
Immune Checkpoint Inhibitor
100%
Overall Survival
60%
Mitogen Activated Protein Kinase Kinase Inhibitor
40%
Monotherapy
20%
Recurrent Disease
20%
Death Receptor
20%
Brain Metastasis
20%
Pembrolizumab
20%
Cytotoxic T Lymphocyte Antigen 4
20%